-
AJH: Anti-myeloma treatment outcomes after BCMA CAR-T for multiple myeloma still need to be improved
Time of Update: 2022-10-12
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
-
Anti-BCMA CAR-T therapy is effective for relapsed and refractory multiple myeloma
Time of Update: 2021-10-01
In the latest development of the therapy, a Phase 1b/2, open-label clinical trial of CAR-T ciltacabtagene autoleucel that targets BCMA, funded by a pharmaceutical manufacturer, evaluated patients with relapsed or refractory MM who have undergone extensive treatment The overall response rate (ORR) and toxicity after CAR-T treatment .
-
NEJM: The effect of anti-B cell maturation antigen CAR-T cell therapy bb2121 in the treatment of multiple myeloma
Time of Update: 2021-05-20
gov/31042825/" target="_blank" rel="noopener">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma .
gov/31042825/" target="_blank" rel="noopener">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma in this message
-
Lancet Haematol: Combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells or a new
Time of Update: 2021-05-20
Researchers from the Affiliated Hospital of Xuzhou Medical University in China conducted a single-center, single-arm, phase 2 clinical trial to evaluate the combination of humanized anti-CD19 and anti-BCMA CAR T cells in relapsed or refractory multiple myeloma The results of the study on activity and safety in patients have been published in Lancet Haematol.
-
AACR 2021: Anti-CD47 antibody AO-176 treats solid tumors and multiple myeloma, with positive results in preclinical trials
Time of Update: 2021-03-19
In addition to blocking the external signal, AO-176 also have other mechanisms, including direct tumor cell killing induced and DAMPs (damage associated molecular patterns), leading to immune immunogenic cell death.
-
Ocean-sourced anti-cancer drug Alidin approved: the first new type of multiple myeloma therapy
Time of Update: 2021-02-17
Recently, the company announced that the Australian Medicines Agency (TGA) has approved the drug Alidin (plitidepsin) for the treatment of patients with recurring or resuscable multiple myeloma (MM) who have failed or are resistant to other therapies.
-
ASH2020 |。 Pfizer Announces CD3 Double Anti-Treatment of Multiple Myeloma ...
Time of Update: 2021-01-06
On December 7, Pfizer released data on the safety and effective of its Phase I Clinical Study (NCT03269136) for the treatment of recurring/refractic multiple myeloma (MM) targeting B-cell mature antigens (BCMA)-CD3 dual-specific antibodies PF-06863135.
-
ASH2020 |。 Pfizer releases CD3 dual anti-treatment multiple myeloma Phase I data
Time of Update: 2020-12-22
the main purpose of this study was to assess the safety and toerability of PF-06863135 injections under the skin to determine the maximum to-dosage for patients and to determine the optimal dose of the phase II clinical study.
these data, the recommended dose for Phase II clinical studies is set at 1,000 μg/kg per week.
-
Leukemia: Dalatumantin anti-Calainadamine and dexamisong are treated with relapsed/incurable multiple myeloma
Time of Update: 2020-12-15
results showed that after 44.3 months of medium follow-up, D-Rd extended the progression-free lifetime (PFS) of the intended treatment population and patient subse group (middle 44.5 vs.
-
Clin Cancer Res: Anti-ICAM1 antibody-drug coupled for potential activity of multiple myeloma.
Time of Update: 2020-10-03
researchers linked anti-ICAM1 monoclonal antibodies to Raoxitin derivatives and tested them in a variety of multiple myeloma cell line, in-place transplant models, and patient samples.
recommend that the toxicity, safety and clinical efficacy of anti-ICAM1 antibody-drug couples should be further evaluated in patients with relapsed or refrmmune multiple myeloma.
-
GSK's anti-BCMA drug for multiple myeloma has been approved and is back in the anti-tumor field.
Time of Update: 2020-08-22
see: Key research on the anti-BCMA drug belantamab mafodotin for multiple myeloma reaches its main end point, but eye toxicity is also of concern: antibody-drug concatenation Belanamab mafodotin: Alarming eye toxicity At the end of May this year, GSK published the study's 13-month follow-up data at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO).
-
EHA 2020: New anti-cancer peptide-drug conjugate Melflufen treatment of refractive multiple myeloma, Phase 2 HORIZON trial successful
Time of Update: 2020-06-25
At the 25th Meeting of the European Hematology Association, Oncopeptides announced the main results of the Phase 2 HORIZON study on the treatment of patients with recurrent refractive merilloma (RRM
-
preparation has been approved by the European Union: the first myeloma subcutaneous CD38 target anti-cancer drug!
Time of Update: 2020-06-17
, 2020 / PRNewswire/ -- The European Commission (EC) recently approved The Johnson and Johnson (JNJ) heavy myeloma drug Darzalex ,®, generic name: daratumab, Darree Subcutaneous (SC) preparations f
-
Blood: The efficacy of Daremu mono-anti-to-take-to-natamine-borazonandand and dexamethasone to treat newly diagnosed transplantable multiple myeloma
Time of Update: 2020-05-29
Self-stem cell transplantation (ASCT) after treatment with Nalaamine, boronitami and Dexameton (RVd) is the standard first-line therapy for newly diagnosed patients with multiple myeloma (NDMM) for
-
Domestic anti BCMA car-t cell therapy! Keji biological ct053 has obtained the qualification of American FDA orphan drug to treat multiple myeloma!
Time of Update: 2019-08-31
August 31, 2019 / BIOON / -- carsgen therapeutics (Shanghai) Co., Ltd (hereinafter referred to as "carsgen therapeutics") is a clinical stage immunooncology company, which is committed to the developm